LILRB1 and neoplasm: Mice treated with two doses of either LILRB1 CAR-T cells or CD19 CAR-T cells exhibited a significant reduction in tumor burden, as measured by bioluminescent imaging (Fig. 7B, C), and had markedly prolonged survival compared to those receiving MOCK T cells (Fig. 7D).